VIRX Insider Trading Activity and SEC Form 4 Filings
VIRX insider trading summary
No open-market insider purchases or sales of Viracta Therapeutics, Inc. (VIRX) have been reported on SEC Form 4 in the past 12 months.
Latest VIRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 27, 2024 | Daniel R. Chevallard | CFO and COO | Sell | $2K (3,405 @ $0.73) |
| Dec 1, 2023 | Mark Rothera | President and CEO | Buy | $24K (47,906 @ $0.49) |
| Nov 30, 2023 | Mark Rothera | President and CEO | Buy | $26K (52,094 @ $0.49) |
| Nov 28, 2023 | Daniel R. Chevallard | CFO and COO | Sell | $2K (3,720 @ $0.50) |
| Aug 28, 2023 | Daniel R. Chevallard | CFO and COO | Sell | $5K (3,512 @ $1.45) |
| May 25, 2023 | Daniel R. Chevallard | CFO and COO | Sell | $5K (3,635 @ $1.42) |
| Feb 27, 2023 | Daniel R. Chevallard | CFO and COO | Sell | $6K (3,599 @ $1.68) |
| Feb 27, 2023 | Lisa Rojkjaer | Chief Medical Officer | Sell | $4K (2,156 @ $1.68) |
| Nov 28, 2022 | Lisa Rojkjaer | Chief Medical Officer | Sell | $6K (2,116 @ $2.72) |
| Nov 28, 2022 | Daniel R. Chevallard | CFO and COO | Sell | $10K (3,532 @ $2.72) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.